Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Lineage Cell Therapeutics (LCTX) Return on Assets: 2011-2025

Historic Return on Assets for Lineage Cell Therapeutics (LCTX) over the last 14 years, with Sep 2025 value amounting to -0.35%.

  • Lineage Cell Therapeutics' Return on Assets fell 15.00% to -0.35% in Q3 2025 from the same period last year, while for Sep 2025 it was -0.35%, marking a year-over-year decrease of 15.00%. This contributed to the annual value of -0.17% for FY2024, which is 2.00% up from last year.
  • Per Lineage Cell Therapeutics' latest filing, its Return on Assets stood at -0.35% for Q3 2025, which was down 13.74% from -0.31% recorded in Q2 2025.
  • Over the past 5 years, Lineage Cell Therapeutics' Return on Assets peaked at -0.10% during Q3 2021, and registered a low of -0.36% during Q3 2022.
  • Its 3-year average for Return on Assets is -0.23%, with a median of -0.21% in 2023.
  • Its Return on Assets has fluctuated over the past 5 years, first climbed by 29bps in 2021, then fell by 26bps in 2022.
  • Over the past 5 years, Lineage Cell Therapeutics' Return on Assets (Quarterly) stood at -0.28% in 2021, then rose by 7bps to -0.21% in 2022, then remained steady at -0.21% in 2023, then increased by 3bps to -0.18% in 2024, then decreased by 15bps to -0.35% in 2025.
  • Its Return on Assets was -0.35% in Q3 2025, compared to -0.31% in Q2 2025 and -0.16% in Q1 2025.